C2 and neoplasm: However, AdKi67-DsRed, AdKi67-CCL5, AdKi67-C2, or AdKi67-C3 combined with B7H3-CAR-T exhibited a significantly improved antitumor efficacy, especially for AdKi67-C3 + CAR-T treatment, with long-term tumor-specific immune surveillance in solid tumors.